Premium
The efficacy of amelxanox OraDisc TM on the prevention of recurrent minor aphthous ulceration
Author(s) -
Murray B.,
Biagioni P. A.,
Lamey P.J.
Publication year - 2006
Publication title -
journal of oral pathology and medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.887
H-Index - 83
eISSN - 1600-0714
pISSN - 0904-2512
DOI - 10.1111/j.1600-0714.2006.00379.x
Subject(s) - medicine , erythema , randomized controlled trial , exact test , dermatology , surgery , gastroenterology
Background: The study was designed to determine the efficacy of OraDisc TM (active component 2 mg amlexanox) on the prevention of aphthous ulcers treated at the prodromal stage. Methods: Thermographic imaging was used to confirm the presence of a prodromal ulcer. Fifty‐two patients were randomized to receive OraDisc TM ( N = 26) or vehicle patches ( N = 26). Patches were applied four times a day for 72 h over the prodromal area. The percentage of subjects who developed an ulcer at 72 h was compared between groups using the Fisher's exact test. Results: About 50% of subjects in the OraDisc TM group developed an ulcer by day 4 compared with 69% in the vehicle group. Erythema score, ulcer size, pain scores and thermographically active area and temperature all showed trends towards healing in the OraDisc TM group. Conclusion: The OraDisc TM prevents ulcers from developing when compared with the vehicle patch.